Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial

Authors

  • Anssi Auvinen,

    Corresponding author
    1. School of Public Health, University of Tampere, Tampere, Finland
    • School of Public Health, University of Tampere, FIN-33016 Tampere, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

    • Fax +358-3-2156 057

  • Liisa Määttänen,

    1. Finnish Cancer Registry, Helsinki, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

  • Patrik Finne,

    1. Department of Clinical Chemistry, Helsinki University Hospital, Helsinki, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

  • Ulf-Håkan Stenman,

    1. Department of Clinical Chemistry, Helsinki University Hospital, Helsinki, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

  • Jussi Aro,

    1. Department of Urology, Helsinki University Hospital, Helsinki, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

  • Harri Juusela,

    1. Department of Surgery, Jorvi Hospital, Espoo, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

  • Sakari Rannikko,

    1. Department of Urology, Helsinki University Hospital, Helsinki, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

  • Teuvo L.J. Tammela,

    1. Department of Urology, Tampere University Hospital, Tampere, Finland
    2. Medical School, University of Tampere, Tampere, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.

  • Matti Hakama

    1. School of Public Health, University of Tampere, Tampere, Finland
    2. Finnish Cancer Registry, Helsinki, Finland
    Search for more papers by this author
    • The authors have not entered into any agreement that could interfere with their access to the data or their ability to analyze the data independently, to prepare manuscripts and to publish them.


Abstract

We estimated the sensitivity of serum prostate-specific antigen (PSA) as a screening test for prostate cancer in the Finnish randomised, population-based prostate cancer screening trial. The study population consisted of 80,458 men aged 55–67 years identified from the national population registry and randomised to the screening or control arm of the trial. The screening algorithm was based on determination of serum PSA concentration. Test sensitivity was estimated based on interval cancer incidence during the first 4 years of follow-up among screening participants with a negative screening test. Interval cancers were defined as those occurring among men with a negative screening test. Altogether, 19 interval cancers were detected among 17,897 men with serum PSA < 3 ng/ml during the first screening interval. A further 5 cases were diagnosed among 811 men with PSA 3.0–3.9 ng/ml with a benign digital rectal examination or free total PSA ratio ≥ 0.16. Test sensitivity based on serum PSA of 3 ng/ml was estimated to be 0.89 (95% confidence interval 0.84–0.93) and that based on PSA of 4 ng/ml combined with an ancillary test (digital rectal examination or free total PSA ratio in the PSA range 3.0–3.9) was 0.87 (0.82–0.92). Test sensitivity achieved with serum PSA in prostate cancer screening appears excellent in the context of a population-based effectiveness trial. © 2004 Wiley-Liss, Inc.

Ancillary